Centrais Electricas Brasileiras S.A.- Eletrobras (NYSE:EBR)
Centrais Electricas Brasileiras S.A.- Eletrobras (NYSE:EBR) represented a move of 0 percent or $0.19 per share and closed its previous day trading session at $6.32. 0 Shares were traded in the last trading session with an Average Volume of 630.06 Million Shares. The stock currently has a Market Capitalization of 8.55 Billion.
Electrobras is involved in the Utilities Industry. Their principal activity is the generation and distribution of electric power through their companies to the whole of Brazil. Some of their other activities include development of technology programs, technical standards and industrial quality.
The stock traded between $3.14 and $7.86 over 1-Year time period showing its price to sales ratio of 0.95. Centrais Electricas Brasileiras S.A.- Eletrobras (NYSE:EBR) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $9.33 and 200-Day Simple Moving Average of $23.7. Its Price to Free Cash Flow is 0 and Price to Book of 0.75.
Analyst’s recommended the stock as 0 where 1 represents Strong Buy and 5 represents Sell.
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)
In the last trading session, Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) added its value by 0% closing at the price of $4.74. The stock currently has market capitalization of 105.23 Million, with average volume of 291.72 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is showing beta of -0.98. This particular value of beta suggests that Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) has historically moved -98% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is at $-0.31.
The stock currently has RSI of 57.83. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) topped its 52-week high price of $5.79 on 11/16/18 and 52-Week Low Price of $1.45 on 01/26/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.34% and monthly volatility of 9.75% respectively.